CellCept Shortage: What Providers and Prescribers Need to Know in 2026

Mycophenolate mofetil (CellCept) remains a cornerstone of modern transplant immunosuppression, used in the majority of kidney, heart, and liver transplant regimens. As a prescriber, you have likely fielded calls from transplant patients unable to fill their mycophenolate prescriptions at local pharmacies. This briefing summarizes the current supply situation and provides actionable clinical guidance.

Current Supply Situation (2026 Update)

Brand-name CellCept (Genentech) is not on the FDA's formal shortage list and maintains generally adequate supply through specialty and mail-order pharmacies. The supply disruption is concentrated in the generic market.

ASHP has documented shortage listings for generic mycophenolate mofetil capsules and tablets from multiple manufacturers including Hikma, Mylan, Sandoz, Accord, and Ascend — encompassing both 250 mg capsules and 500 mg tablets. Generic mycophenolate sodium delayed-release tablets (Myfortic equivalents) have also experienced intermittent shortage listings from Apotex and Major.

The pattern is best characterized as uneven distribution rather than a complete supply collapse. Medication is being manufactured and reaching the market, but allocation practices by wholesalers, combined with concentrated demand at high-volume pharmacy chains, are creating stock gaps at the retail pharmacy level.

Clinical Implications for Your Patient Population

The clinical stakes of mycophenolate supply disruptions vary considerably by patient population:

Kidney transplant recipients: Even brief immunosuppression gaps carry acute rejection risk. MMF is the primary antiproliferative agent in most protocols. Early refills and 90-day supply prescriptions are strongly advisable.

Heart transplant recipients: Heart transplant patients typically require higher MMF doses (1.5 g BID). Supply disruptions are particularly concerning given the higher standard daily dose and the clinical consequences of cardiac allograft rejection.

Liver transplant recipients: Liver transplant protocols often include MMF, though some programs use it at lower doses or taper it over time. The immunological stakes remain significant.

Autoimmune disease patients (off-label use): For lupus nephritis, vasculitis, or autoimmune hepatitis, supply gaps may allow for a planned bridge to an alternative such as azathioprine — but this requires careful monitoring for disease flare.

Prescribing Strategies to Mitigate Supply Risk

Prescribe 90-day supplies. For stable maintenance transplant patients, 90-day fills through a specialty or mail-order pharmacy significantly reduce exposure to retail-level stock gaps.

Partner with your transplant pharmacy. Specialty pharmacies serving transplant centers maintain more reliable MMF inventory. Ensure your patients are using your center's preferred pharmacy.

Write 'brand medically necessary' when indicated. For patients who cannot access generic MMF, specifying brand CellCept on the prescription allows dispensing of the Genentech product, which maintains adequate supply. Genentech's co-pay card can reduce patient costs to $15/month for commercially insured patients.

Maintain consistent manufacturer when possible. Some transplant centers prefer to keep patients on a single generic manufacturer to minimize intrapatient variability in drug exposure. If a manufacturer change is necessary due to shortage, consider monitoring drug levels (if your protocol includes them) more closely in the near term.

Consider Myfortic for GI-intolerant patients. Some patients with CellCept-related GI toxicity can tolerate Myfortic better. Note: brand Myfortic and Mylan's generic are generally available; some other generic manufacturers have had shortage listings.

When to Consider Alternative Antiproliferative Agents

Switching antiproliferative agents during a shortage should be the last resort, not the first. However, if MMF/MPA supply cannot be secured through all available channels, consider:

Azathioprine (Imuran): For tacrolimus-based regimens, evidence supports azathioprine as a reasonable antiproliferative alternative, particularly in immunologically low-risk transplant patients. TPMT/NUDT15 testing should be performed before initiation. Azathioprine is oral tablet availability is generally better than generic MMF currently.

Sirolimus: An mTOR inhibitor option for kidney transplant patients; contraindicated in liver transplant (hepatic artery thrombosis risk). Not appropriate for immediate post-transplant use due to wound healing impairment.

Patient Access Tool for Your Practice

medfinder is a service that calls pharmacies near your patients to check real-time CellCept availability. Transplant coordinators and pharmacists can direct patients to medfinder for providers as a way to systematically locate stock without patients spending hours on hold.

For a patient-facing overview of the shortage, refer to: CellCept Shortage Update: What Patients Need to Know in 2026.